Sodium oxybate and Stadol NS nasal
Determining the interaction of Sodium oxybate and Stadol NS nasal and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: The central nervous system and respiratory depressant effects of sodium oxybate, which is the sodium salt of gamma hydroxybutyrate (GHB), may be potentiated by concomitant use of other agents with CNS depressant effects. An increased risk of serious adverse reactions such as respiratory depression, hypotension, profound sedation, syncope, coma, and even death should be considered. MANAGEMENT: Concomitant use of sodium oxybate with other CNS depressants should be avoided whenever possible. Otherwise, close monitoring and/or dosage reductions should be considered. If short-term use of a CNS depressant is required (e.g., post- or perioperative opioid), a temporary interruption of sodium oxybate therapy may be appropriate. All patients treated with sodium oxybate should be advised not to drive, operate machinery, or engage in hazardous activities requiring mental alertness and motor coordination for at least 6 hours after taking the second nightly dose of sodium oxybate and until they know how the medication affects them. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 "Product Information. Xyrem (sodium oxybate)." Orphan Medical, Minnetonka, MN.
Professional:GENERALLY AVOID: The central nervous system and respiratory depressant effects of sodium oxybate, which is the sodium salt of gamma hydroxybutyrate (GHB), may be potentiated by concomitant use of other agents with CNS depressant effects. An increased risk of serious adverse reactions such as respiratory depression, hypotension, profound sedation, syncope, coma, and even death should be considered.
MANAGEMENT: Concomitant use of sodium oxybate with other CNS depressants should be avoided whenever possible. Otherwise, close monitoring and/or dosage reductions should be considered. If short-term use of a CNS depressant is required (e.g., post- or perioperative opioid), a temporary interruption of sodium oxybate therapy may be appropriate. All patients treated with sodium oxybate should be advised not to drive, operate machinery, or engage in hazardous activities requiring mental alertness and motor coordination for at least 6 hours after taking the second nightly dose of sodium oxybate and until they know how the medication affects them.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Xyrem (sodium oxybate)." Orphan Medical, Minnetonka, MN.
Generic Name: sodium oxybate
Brand name: Xyrem
Synonyms: Sodium Oxybate
Generic Name: butorphanol
Brand name: Stadol NS, Stadol
Synonyms: Stadol NS (nasal), Stadol
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Sodium oxybate-Stagesic
- Sodium oxybate-Stahist AD
- Sodium oxybate-Stahist AD (Chlorcyclizine and Pseudoephedrine Liquid)
- Sodium oxybate-Stahist AD (Chlorcyclizine and Pseudoephedrine Tablets)
- Sodium oxybate-Stalevo
- Sodium oxybate-Stalevo 100
- Stadol NS nasal-Sodium phenylacetate and benzoate Intravenous
- Stadol NS nasal-Sodium Phenylacetate and Sodium Benzoate
- Stadol NS nasal-Sodium Phenylacetate and Sodium Benzoate Injection
- Stadol NS nasal-Sodium phenylbutyrate
- Stadol NS nasal-Sodium Phenylbutyrate Powder
- Stadol NS nasal-Sodium Phenylbutyrate Tablets